These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 37344759)

  • 1. Current status and advances in esophageal drug delivery technology: influence of physiological, pathophysiological and pharmaceutical factors.
    Lim AW; Talley NJ; Walker MM; Storm G; Hua S
    Drug Deliv; 2023 Dec; 30(1):2219423. PubMed ID: 37344759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The challenges of drug delivery to the esophagus and how to overcome them.
    Krause J; Brokmann F; Rosenbaum C; Weitschies W
    Expert Opin Drug Deliv; 2022 Feb; 19(2):119-131. PubMed ID: 35062853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies and therapeutic opportunities for the delivery of drugs to the esophagus.
    Zhang L; Russell D; Conway BR; Batchelor H
    Crit Rev Ther Drug Carrier Syst; 2008; 25(3):259-304. PubMed ID: 18540840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in Nanoparticulate Drug Delivery Approaches for Sublingual and Buccal Administration.
    Hua S
    Front Pharmacol; 2019; 10():1328. PubMed ID: 31827435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioadhesive dosage forms for esophageal drug delivery.
    Batchelor H
    Pharm Res; 2005 Feb; 22(2):175-81. PubMed ID: 15783063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in Oral Drug Delivery for Regional Targeting in the Gastrointestinal Tract - Influence of Physiological, Pathophysiological and Pharmaceutical Factors.
    Hua S
    Front Pharmacol; 2020; 11():524. PubMed ID: 32425781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orodispersible tablets for pediatric drug delivery: current challenges and recent advances.
    Wiedey R; Kokott M; Breitkreutz J
    Expert Opin Drug Deliv; 2021 Dec; 18(12):1873-1890. PubMed ID: 34822316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neonatal and pediatric oral drug delivery: Hopes and hurdles.
    Mfoafo KA; Omidian M; Bertol CD; Omidi Y; Omidian H
    Int J Pharm; 2021 Mar; 597():120296. PubMed ID: 33524524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 10 years EU regulation of pediatric medicines - impact on cardiovascular drug formulations.
    Thabet Y; Slavkova M; Breitkreutz J
    Expert Opin Drug Deliv; 2018 Mar; 15(3):261-270. PubMed ID: 29284286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nicotine replacement therapy for smoking cessation.
    Stead LF; Perera R; Bullen C; Mant D; Hartmann-Boyce J; Cahill K; Lancaster T
    Cochrane Database Syst Rev; 2012 Nov; 11():CD000146. PubMed ID: 23152200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in drug delivery systems: Work in progress still needed?
    Laffleur F; Keckeis V
    Int J Pharm; 2020 Nov; 590():119912. PubMed ID: 32971178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formulations of Topical Steroids in Eosinophilic Esophagitis-Current Treatment and Emerging Possibilities.
    Główczewski A; Krogulska A
    J Clin Med; 2022 Mar; 11(5):. PubMed ID: 35268544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue.
    Hua S; Marks E; Schneider JJ; Keely S
    Nanomedicine; 2015 Jul; 11(5):1117-32. PubMed ID: 25784453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral Modified Drug Release Solid Dosage Form with Special Reference to Design; An Overview.
    Murugesan S; Gowramma B; Lakshmanan K; Reddy Karri VVS; Radhakrishnan A
    Curr Drug Res Rev; 2020; 12(1):16-25. PubMed ID: 31755398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orodispersible dosage forms: biopharmaceutical improvements and regulatory requirements.
    Cilurzo F; Musazzi UM; Franzé S; Selmin F; Minghetti P
    Drug Discov Today; 2018 Feb; 23(2):251-259. PubMed ID: 29030242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted localized use of therapeutic antibodies: a review of non-systemic, topical and oral applications.
    Jones RG; Martino A
    Crit Rev Biotechnol; 2016; 36(3):506-20. PubMed ID: 25600465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patent Perspective on Orodispersible Films.
    Gupta S; Kumar TP; Gowda DV
    Recent Pat Drug Deliv Formul; 2020; 14(2):88-97. PubMed ID: 32885766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.